Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.

PLoS One · 2018 · PMC5955528 · PMID 29768414

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Visual evoked potential-VEP and median nerve SEP (N13-N20) also showed a trend of stabilization or amelioration of latencies over time in treatment groups, although these differences didn ́t reach statistically significance over the time, as well as between groups;(p.F = 0,59; p.kW = 0,89).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.